Role of Spironolactone Chalcone in the Prevention of Peritoneal Fibrosis in Patients with Peritoneal Dialysis
Purpose: The study was designed to investigate the effects of a novel spironolactone chalcone in the prevention of peritoneal fibrosis.
Methods: Wistar rats (n = 30) were randomly assigned to 3 groups: bacteria (B), spironolactone amide treatment (S), and control (C) groups. C group received only dextran beads while S and B groups were given bacteria and dextran beads intraperitoneally, but spironolactone chalcone was also given to S group. The treatments were administered daily. The rats were sacrificed on day 15 to quantify peritoneal adhesion and for histological examination of the peritoneal tissues using hematoxylin, eosin and Masson’s trichrome dyes. Enzyme-linked immunosorbent assay (ELISA) kit was used to determine TGFβ1 content of peritoneal fluids and serum samples.
Results: Spironolactone chalcone treatment at a dose of 30 mg/kg body weight daily for 15 days significantly reduced peritoneal total adhesion score in S group compared to untreated B group (p < 0.01). S group also showed significantly lower mean peritoneal thickness, inflammation score, and fibrosis score compared to B group. Serum transforming growth factor β1 was also reduced significantly in S group animals on spironolactone chalcone treatment compared to B group.
Conclusion: Spironolactone chalcone is a potentially effective candidate for decreasing the extent of peritoneal injury caused by bacterial peritonitis.
Keywords: Peritoneal thickness, Inflammation score, Adhesion score, Bacterial peritonitis, Peritoneal fluids
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.